Detalles de la búsqueda
1.
Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade.
Blood;
142(16): 1359-1370, 2023 Oct 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37339586
2.
Coronary artery calcium and cardiovascular outcomes in patients with lymphoma undergoing autologous hematopoietic cell transplantation.
Cancer;
2024 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-38358333
3.
Response-adapted anti-PD-1-based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE.
Blood;
139(25): 3605-3616, 2022 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-35316328
4.
Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma.
Blood;
140(25): 2697-2708, 2022 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35700381
5.
Cost-effectiveness of second-line axicabtagene ciloleucel in relapsed refractory diffuse large B-cell lymphoma.
Blood;
140(19): 2024-2036, 2022 11 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-35914220
6.
Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.
Haematologica;
109(2): 533-542, 2024 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37470137
7.
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
Ann Hematol;
103(1): 185-198, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37851072
8.
Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates.
Oncologist;
28(9): e843-e846, 2023 09 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37335880
9.
Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma.
Haematologica;
108(1): 98-109, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35833303
10.
The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis.
Haematologica;
108(1): 150-160, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35443559
11.
Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy.
J Natl Compr Canc Netw;
21(4): 373-382.e1, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-37015335
12.
Bendamustine lymphodepletion is a well-tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B-cell lymphoma.
Am J Hematol;
98(11): 1751-1761, 2023 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37668287
13.
Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma.
Blood;
133(4): 306-318, 2019 01 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30530749
14.
Acute Promyelocytic Leukemia: Update on Risk Stratification and Treatment Practices.
Cancer Treat Res;
181: 45-55, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34626354
15.
Current and Emerging Therapies for Acute Myeloid Leukemia.
Cancer Treat Res;
181: 57-73, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34626355
16.
Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant;
26(8): 1425-1432, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32416253
17.
Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia.
Biol Blood Marrow Transplant;
26(6): 1084-1090, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32035275
18.
Outcome of Allogeneic Hematopoietic Cell Transplantation after Venetoclax and Hypomethylating Agent Therapy for Acute Myelogenous Leukemia.
Biol Blood Marrow Transplant;
26(12): e322-e327, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-32866594
19.
Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center.
Biol Blood Marrow Transplant;
26(2): 292-299, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31536825
20.
Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation.
Cancer;
126(10): 2279-2287, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32049359